1 / 29

The concept of Diabetes & CV risk: A lifetime risk challenge

Master Class Lipid Innovations Prague, Czech Republic May 27-28 , 2011. The concept of Diabetes & CV risk: A lifetime risk challenge. Presentation topic.

candra
Télécharger la présentation

The concept of Diabetes & CV risk: A lifetime risk challenge

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. MasterClassLipidInnovations Prague, Czech Republic May 27-28, 2011 The concept of Diabetes & CV risk:A lifetime risk challenge Presentation topic Vascular function as an early sign of trouble: How can the inhibition of cholesterol absorption reduce the atherogenic load of intestinal lipoproteins? Slide lecture prepared and held by: Prof Frank Visseren, MD Academic Medical Centre Utrecht The Netherlands

  2. Overview of Cholesterol Transport

  3. Cholesterol transporter Altman SW et al. Science 2004;303:1201-1204

  4. Postprandiallipidemia Postprandial lipids (triglyceride-rich lipoprotein or lipoprotein-remnant particles) are associated with: • Endothelial dysfunction • Elevated small LDL particles • Elevated Factor VII • Elevated plasminogen activator inhibitor-1 (PAI-1) • Elevated C-reactive protein (CRP)

  5. Copenhagen City Heart Study Nordestgaard B, et al. JAMA 2007;298:299-308.

  6. Triglyceride levels and levels of remnant lipoprotein cholesterol since last meal Nordestgaard B, et al. JAMA 2007;298:299-308.

  7. Levels of Remnant Lipoprotein Cholesterol as a function of levels of nonfasting Triglycerides Nordestgaard B, et al. JAMA 2007;298:299-308.

  8. Non-fasting triglycerides and risk for MI, IHD and death in Women Nordestgaard B, et al. JAMA 2007;298:299-308.

  9. Non-fasting triglycerides and risk for MI, IHD and death in Men Nordestgaard B, et al. JAMA 2007;298:299-308.

  10. Women’s Health Study (WHS) Bansal S, et al. JAMA 2007;298:309-316.

  11. Association of triglyceride levels with incident CVD according to fasting status Bansal S, et al. JAMA 2007;298:309-316.

  12. Womens Health Study (WHS) Bansal S, et al. JAMA 2007;298:309-316.

  13. Triglyceride concentrations after an oral fatload in obese patients with metabolic syndrome Olijhoek et al. J CardiovascPharmacol 2008;52:145-150

  14. Drop in HDL-c after an oral fatload N=19 Hajer et al. ClinEndocrinol 2008;69:870-877

  15. Increase in Cholesterol Ester Transfer (CET) after an oral fatload N=19 Hajer et al. Clin Endocrinol 2008;69:870-877

  16. Oral Triglyceride Tolerance Test!?? Standardized Oral Triglyceride Tolerance Test (OTTT): • 1g dairy cream/kg body weight • 50g fat plus 50 g carbohydrate • Mixed meal But: No evidence for CVD risk stratification No evidence for clinical benefit of treatment of postprandial lipids

  17. Effect of statin versus fibrate on postprandial endothelial dysfunction: role of remnant-like particles Randomized, placebo controlled trial Cerivastatin 0.4mg vs. gemfibrozil 900mg 15 healthy volunteers Wilmink H et al. CardiovascRes 2001;50:577-582

  18. Ezetimibe improves postprandial hyperlipemia and its induced endothelial dysfunction N=19 Yunoki K et al. Atherosclerosis 2011;epub

  19. Ezetimibe improves postprandial hyperlipemia and its induced endothelial dysfunction N=19 Yunoki K et al. Atherosclerosis 2011;epub

  20. Low-dose statin and ezetimibe compared to high-dose simvastatin on postprandial lipids in patients with the metabolic syndrome 6 weeks 4 weeks 6 weeks Simva/eze 10/10 washout Simva 80mg FMD FMD washout Simva 80mg Simva/eze 10/10 Oral fatload Oral fatload Olijhoek et al. J Cardiovasc Pharmacol 2008;52:145-150

  21. Low-dose statin and ezetimibe compared to high-dose simvastatin on postprandial lipids in patients with the metabolic syndrome Oral fatloading test Olijhoek et al. J CardiovascPharmacol 2008;52:145-150

  22. Low-dose statin and ezetimibe compared to high-dose simvastatin on postprandial lipids in patients with the metabolic syndrome p<0.001 Olijhoek et al. J CardiovascPharmacol 2008;52:145-150

  23. Low-dose statin and ezetimibe compared to high-dose simvastatin on postprandial lipids in patients with the metabolic syndrome Olijhoek et al. J CardiovascPharmacol 2008;52:145-150

  24. Conclusions • HDL-c drops after an oral fatload • Statins, fibrates, statin/ezetimibe lower post-fatloadhyperlipidemia (triglycerides, LDL-c, remnant particles) • Statinmonotherapy and Ezetimibemonotherapy preserve post-fatload endothelial function • Combination of low-dose statine with ezetimibe preserve post-fatload endothelial function But: small studies

  25. The PostprAndialeNdothelial function After Combination of Ezetimibe and simvAstatin (PANACEA) Study

  26. ThePostprAndialeNdothelial function After Combination of Ezetimibe and simvAstatin (PANACEA) Study Primary objective: To evaluate the effect of simvastatin/ezetimibe or high-dose simvastatin alone on fasting and postprandial endothelial function as measured with FMD and EndoPat in obese patients with metabolic syndrome.

  27. ThePostprAndialeNdothelial function After Combination of Ezetimibe and simvAstatin (PANACEA) Study Study design: Randomized, double blind 2 period cross-over 100 patients 5 centers in The Netherlands and Spain 6 weeks simvastatin 80mg 6 weeks simvastatin/ezetimibe 10/10mg

  28. PANACEA trial design Parallel study A B Cross-over study A A B B

  29. Conclusions • Non-fasting triglycerde plasma levels are associated with increased CVD risk • In the postprandial phase HDL-c plasma levels drop • Postprandial hyperlipidemia can be reduced with lipid-lowering therapy • Postprandial endothelial dysfunction can be diminished by lipid-lowering therapy • Although an appealing pathophysiological concept, the clinical usefulness of postprandial hyperlipidemia remains to be determined

More Related